Survey Makes Positive Comments Regarding Medtronic's (MDT) Meniett Therapy
Results of a survey published in the August 2007 issue of Otology & Neurotology indicates that the Meniett Low Pressure Pulse Generator manufactured by Medtronic, Inc. (NYSE: MDT) is the preferred treatment method after diet modification for patients diagnosed with Meniere's Disease in an only hearing ear. The survey was conducted among a nonrandom sample of clinically active members of the American Otological Society and the American Neurotology Society by researchers from the Division of Otolaryngology - Head and Neck Surgery at Penn State Milton S. Hershey Medical Center.
When asked what they would offer if initial treatment failed, respondents chose the Meniett® device first and most frequently over therapies such as intratympanic corticosteroids, endolymphatic sac mastoid shunt, intratympanic gentamicin perfusion and endolymphatic sac vein decompression.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
-0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
